Last reviewed · How we verify
DMB-I (INN: Latrepirdine)
Latrepirdine is a neuroprotective agent that modulates mitochondrial function and reduces neuronal excitotoxicity through multiple pathways including NMDA receptor antagonism and monoamine oxidase inhibition.
Latrepirdine is a neuroprotective agent that modulates mitochondrial function and reduces neuronal excitotoxicity through multiple pathways including NMDA receptor antagonism and monoamine oxidase inhibition. Used for Alzheimer's disease, Mild to moderate cognitive impairment.
At a glance
| Generic name | DMB-I (INN: Latrepirdine) |
|---|---|
| Also known as | Latrepirdine, Dimebon® |
| Sponsor | Bigespas LTD |
| Drug class | Neuroprotective agent |
| Target | NMDA receptor, mitochondrial membrane, monoamine oxidase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Latrepirdine acts as a mitochondrial neuroprotectant by stabilizing mitochondrial membrane potential and reducing reactive oxygen species production. It also antagonizes NMDA receptors and inhibits monoamine oxidases, providing multi-target neuroprotection against excitotoxic and oxidative stress-induced neuronal damage.
Approved indications
- Alzheimer's disease
- Mild to moderate cognitive impairment
Common side effects
- Headache
- Dizziness
- Nausea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DMB-I (INN: Latrepirdine) CI brief — competitive landscape report
- DMB-I (INN: Latrepirdine) updates RSS · CI watch RSS
- Bigespas LTD portfolio CI